GEN Exclusives

More »

GEN News Highlights

More »
Mar 24, 2011

Molecular Devices to Distribute ChanTest Ion Channel and GPCR Cell Lines

  • Molecular Devices will distribute ChanTest’s portfolio of ion channel and GPCR cell lines on a nonexclusive basis. In addition, ChanTest's cell-optimization services will be promoted by Molecular Devices to its PatchXpress® 7000A, IonWorks® Quattro, IonWorks Barracuda™, and FLIPR® Tetra system customers worldwide.

    ChanTest has a portfolio of more than 145 ion channel and 110 GPCR cell lines.

    “Providing more high-quality options to a larger group of customers naturally will bring more visibility to our best-in-class ion channel cell lines and complement them perfectly,” says ChanTest’s founder, Arthur M. Brown, M.D., Ph.D.

    Founded in 1998, ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents. The company has tested compounds for more than 500 global pharmaceutical and biotechnology companies, with which it partners with the goal of speeding up drug development.

    Molecular Devices is a unit of Danaher, which last month announced plans to acquire Beckman Coulter for $6.8 billion.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?